Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
PSDV's Cash-to-Debt is ranked higher than
99% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. PSDV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PSDV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.72
PSDV's Equity-to-Asset is ranked higher than
70% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PSDV: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
PSDV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.71 Max: 0.91
Current: 0.72
0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
99% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. PSDV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PSDV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -16.21
Beneish M-Score: -0.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -264.58
PSDV's Operating Margin % is ranked lower than
91% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. PSDV: -264.58 )
Ranked among companies with meaningful Operating Margin % only.
PSDV' s Operating Margin % Range Over the Past 10 Years
Min: -2445.54  Med: -474.92 Max: 39.44
Current: -264.58
-2445.54
39.44
Net Margin % -262.62
PSDV's Net Margin % is ranked lower than
90% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. PSDV: -262.62 )
Ranked among companies with meaningful Net Margin % only.
PSDV' s Net Margin % Range Over the Past 10 Years
Min: -4638.7  Med: -469.92 Max: 37.97
Current: -262.62
-4638.7
37.97
ROE % -105.19
PSDV's ROE % is ranked lower than
92% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. PSDV: -105.19 )
Ranked among companies with meaningful ROE % only.
PSDV' s ROE % Range Over the Past 10 Years
Min: -133.19  Med: -97.19 Max: 33.15
Current: -105.19
-133.19
33.15
ROA % -72.16
PSDV's ROA % is ranked lower than
92% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. PSDV: -72.16 )
Ranked among companies with meaningful ROA % only.
PSDV' s ROA % Range Over the Past 10 Years
Min: -95.61  Med: -65.97 Max: 23.06
Current: -72.16
-95.61
23.06
ROC (Joel Greenblatt) % -7103.76
PSDV's ROC (Joel Greenblatt) % is ranked lower than
95% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. PSDV: -7103.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PSDV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15359.59  Med: -6301.23 Max: 16680.73
Current: -7103.76
-15359.59
16680.73
3-Year Revenue Growth Rate -18.10
PSDV's 3-Year Revenue Growth Rate is ranked lower than
90% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. PSDV: -18.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PSDV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.8 Max: 365.7
Current: -18.1
0
365.7
3-Year EBITDA Growth Rate 11.30
PSDV's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. PSDV: 11.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PSDV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 933.8
Current: 11.3
0
933.8
3-Year EPS without NRI Growth Rate 9.40
PSDV's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PSDV: 9.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PSDV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.05 Max: 348.3
Current: 9.4
0
348.3
GuruFocus has detected 3 Warning Signs with pSivida Corp $PSDV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PSDV's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PSDV Guru Trades in Q2 2016

Jim Simons 586,900 sh (+2.11%)
Ken Fisher 12,057 sh (unchged)
» More
Q3 2016

PSDV Guru Trades in Q3 2016

Jim Simons 677,100 sh (+15.37%)
Ken Fisher 12,057 sh (unchged)
» More
Q4 2016

PSDV Guru Trades in Q4 2016

Jim Simons 907,000 sh (+33.95%)
Ken Fisher 12,057 sh (unchged)
» More
Q1 2017

PSDV Guru Trades in Q1 2017

Jim Simons 963,043 sh (+6.18%)
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 334516    SIC: 3826
Compare:NAS:GALT, OTCPK:BIOYF, NAS:ARLZ, NAS:TYHT, OTCPK:ACNNF, OTCPK:HYYDF, OTCPK:ICCLF, NAS:MEIP, OTCPK:OWCP, NAS:AGRX, NAS:SPHS, NAS:ADMP, NAS:LPCN, NAS:IMMY, NAS:EPIX, OTCPK:CPHRF, NAS:CPIX, OTCPK:EMMBF, OTCPK:SENZ, OTCPK:MRPHF » details
Traded in other countries:PVA.Australia, PV3.Germany, PSIZF.USA,
Headquarter Location:USA
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.

pSivida Corp was organized as a Delaware Corporation in March 2008. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is engaged in the treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials and uses different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal and marketing authorization is pending in Italy and Spain. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. Its competitors and potential competitors are larger, established and more experienced and have more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.

Top Ranked Articles about pSivida Corp

Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

WATERTOWN, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company’s Durasert three-year treatment for posterior segment uveitis has been accepted for a paper presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting being held in Baltimore, MD from May 7-11, 2017.
The abstract accepted for paper presentation is titled, “An Injectable Fluocinolone Acetonide Intravitreal Insert Decreases the Incidence of Recurrence in Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye: 12 Month Results.” The data will be presented by Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, during the session titled, “Emerging Treatments for Uveitis,” scheduled for Monday, May 8, 2017 from 9:00am to 9:15am ET. “ARVO is one of the most important ophthalmology conferences of the year and we are excited that data from our Phase 3 study has been selected,” commented Nancy Lurker, President and Chief Executive Officer. “Dr. Jaffe is a recognized authority on posterior segment uveitis and we are looking forward to his presentation to this prestigious audience." About Posterior Segment Uveitis Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is a leading cause of blindness in the developed and developing countries. It afflicts people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S., posterior uveitis affects approximately 175,000 people, resulting in approximately 30,000 cases of blindness and making it the third leading cause of blindness in the U.S. Patients with posterior uveitis are typically treated with systemic steroids; but, over time, frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer. About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug technologies for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the US and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis being independently developed, is currently in pivotal Phase 3 clinical trials. pSivida's pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat uveitis, wet and dry age-related macular degeneration, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google . SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; further impairment of our intangible assets; successful commercialization of, and receipt of revenues from, ILUVIEN® for diabetic macular edema (“ILUVIEN”), which depends on Alimera’s ability to continue as a going concern and the effect of pricing and reimbursement decisions on sales of ILUVIEN; safety and efficacy results of the second Durasert three-year uveitis Phase 3 clinical trial and the number of clinical trials and data required for the Durasert three-year uveitis marketing approval applications in the U.S. and EU; our ability to file and the timing of filing and acceptance of the Durasert three-year uveitis marketing approval applications in the U.S. and EU; our ability to use data in a U.S. NDA from clinical trials outside the U.S.; maintenance of European orphan designation for Durasert three-year uveitis; our ability to successfully commercialize Durasert three-year uveitis, if approved; the outcome of a dispute with Alimera regarding commercialization expenses; potential off-label sales of ILUVIEN for uveitis; consequences of fluocinolone acetonide side effects; potential declines in Retisert® royalties; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; efficacy and our future development of an implant to treat severe osteoarthritis; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; our dependence on contract research organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential U.K. exit from the EU; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
EVC Group

Michael Polyviou/Doug Sherk – Investors
[email protected]; [email protected]
212.850.6020; 646-445-4800

Thomas Gibson – Media
[email protected]
201-476-0322

Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.32
PSDV's PB Ratio is ranked lower than
64% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. PSDV: 6.32 )
Ranked among companies with meaningful PB Ratio only.
PSDV' s PB Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.9 Max: 11.73
Current: 6.32
0.01
11.73
PS Ratio 10.62
PSDV's PS Ratio is ranked lower than
79% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PSDV: 10.62 )
Ranked among companies with meaningful PS Ratio only.
PSDV' s PS Ratio Range Over the Past 10 Years
Min: 0.38  Med: 8.13 Max: 130.81
Current: 10.62
0.38
130.81
EV-to-EBIT -3.81
PSDV's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. PSDV: -3.81 )
Ranked among companies with meaningful EV-to-EBIT only.
PSDV' s EV-to-EBIT Range Over the Past 10 Years
Min: -478.6  Med: -3.1 Max: 613.2
Current: -3.81
-478.6
613.2
EV-to-EBITDA -3.99
PSDV's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. PSDV: -3.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
PSDV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1805.5  Med: -2.4 Max: 63.5
Current: -3.99
-1805.5
63.5
Current Ratio 3.33
PSDV's Current Ratio is ranked higher than
66% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. PSDV: 3.33 )
Ranked among companies with meaningful Current Ratio only.
PSDV' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.58 Max: 17.6
Current: 3.33
0.26
17.6
Quick Ratio 3.33
PSDV's Quick Ratio is ranked higher than
73% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. PSDV: 3.33 )
Ranked among companies with meaningful Quick Ratio only.
PSDV' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.58 Max: 17.6
Current: 3.33
0.26
17.6
Days Sales Outstanding 15.33
PSDV's Days Sales Outstanding is ranked higher than
89% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. PSDV: 15.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
PSDV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.55  Med: 81.04 Max: 493.85
Current: 15.33
8.55
493.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
PSDV's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. PSDV: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PSDV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -467.6  Med: -7.9 Max: 0
Current: -13.6
-467.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.65
PSDV's Price-to-Net-Cash is ranked higher than
76% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. PSDV: 7.65 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PSDV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.45  Med: 6.46 Max: 223.64
Current: 7.65
0.45
223.64
Price-to-Net-Current-Asset-Value 6.94
PSDV's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. PSDV: 6.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PSDV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.16  Med: 5.63 Max: 94.62
Current: 6.94
0.16
94.62
Price-to-Tangible-Book 6.61
PSDV's Price-to-Tangible-Book is ranked lower than
55% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. PSDV: 6.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PSDV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.15  Med: 5.58 Max: 33.47
Current: 6.61
0.15
33.47
Price-to-Median-PS-Value 1.30
PSDV's Price-to-Median-PS-Value is ranked higher than
68% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. PSDV: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PSDV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.36 Max: 1360
Current: 1.3
0.08
1360
Earnings Yield (Greenblatt) % -26.25
PSDV's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. PSDV: -26.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PSDV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 7.4 Max: 18.4
Current: -26.25
0.2
18.4

More Statistics

Revenue (TTM) (Mil) $7.14
EPS (TTM) $ -0.55
Beta-1.75
Short Percentage of Float0.40%
52-Week Range $1.50 - 4.25
Shares Outstanding (Mil)39.36
» More Articles for PSDV

Headlines

Articles On GuruFocus.com
Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences May 08 2017 
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th Apr 19 2017 
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 A Mar 15 2017 
Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 

More From Other Websites
ETFs with exposure to pSivida Corp. : May 22, 2017 May 22 2017
pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017 May 10 2017
Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences... May 08 2017
Today's Research Reports on Kratos Defense & Security Solutions and pSivida Post Earnings May 08 2017
Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT May 05 2017
PSivida reports 3Q loss May 04 2017
pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track May 04 2017
Investor Network: pSivida Corp. to Host Earnings Call May 04 2017
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th Apr 19 2017
ETFs with exposure to pSivida Corp. : April 11, 2017 Apr 11 2017
ETFs with exposure to pSivida Corp. : March 30, 2017 Mar 29 2017
pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017 Mar 20 2017
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017... Mar 15 2017
Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT Feb 07 2017
PSivida posts 2Q loss Feb 07 2017
pSivida Corp. (PSDV): Here’s How It Stacks Up Versus Its Peers Dec 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)